key: cord-0899394-ay96ve5z
authors: Lang, Peter; Eichholz, Thomas; Bakchoul, Tamam; Streiter, Monika; Petrasch, Maurice; Bösmüller, Hans; Klein, Reinhild; Rabsteyn, Armin; Lang, Anne-Marie; Adams, Constantin; Klingel, Karin; Gessner, Michaela; Rosenberger, Peter; Ruef, Peter; Handgretinger, Rupert
title: Defibrotide for the treatment of PIMS-TS in two pediatric patients
date: 2020-09-19
journal: J Pediatric Infect Dis Soc
DOI: 10.1093/jpids/piaa117
sha: ca356d9b1c32b67a9a2469ac8cbc35e4b19834e3
doc_id: 899394
cord_uid: ay96ve5z

The pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) is a severe complication of Covid-19. Since impaired coagulation, thrombosis/endotheliitis are suspected pathomechanisms, we treated two patients with defibrotide (DF), a pro-fibrinolytic, antithrombotic, anti-inflammatory oligonucleotide. Symptoms resolved during treatment. Moreover, coagulation parameters indicating hypofibrinolysis and complement activation normalized.

Infection with SARS-CoV-2 virus in adults can cause respiratory failure [1] , impaired coagulations and thromboembolic complications. Especially high levels of D-dimers seem to be a negative prognostic factor [2] . The reason for this might be an endothelial damage not only restricted to the lungs, but affecting the whole organ system resulting in multiorgan failure (MOF) and endothelial cell infection associated with an endotheliitis has been already described in autopsy cases [3] .

More recently, a rare pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection (PIMS-TS) has been described. Presenting signs and symptoms are fever, abdominal pain, cardiac involvement and/or a hyperinflammatory shock [4] , which are also suggestive for endothelial damage.

The sinusoidal obstruction syndrome (SOS) or veno-occlusive disease (VOD) is another disease of the endothelial system which occurs in adults and children after intensive chemo-/radiotherapy in the context of allogeneic stem cell transplantation. It is a serious complication most likely caused by endothelial injuries and consecutive activation of complement with formation of microthrombi mainly in the liver, although any organ can be affected. The A c c e p t e d M a n u s c r i p t 5 endothelial cell injury promotes a pro-thrombotic-hypofibrinolytic state with elevated levels of von Willebrand factor (vWF) and plasminogen activator inhibitor as well as reduced levels of thrombomodulin and tissue plasminogen activator (TPA) [5] .

The only agent with proven efficacy for the treatment of severe SOS is DF, a polydisperse oligonucleotide with pro-fibrinolytic, antithrombotic, antiischemic, anti-inflammatory and anti-adhesive activity [6] . It has been shown that DF protects endothelial cells from toxic, inflammatory and reperfusion damage and might restore the thrombo-fibrinolytic balance by increasing TPA, thrombomodulin and reducing vWF [7] . Given the similarity of the endothelial damage in patients with SOS and the positive action of DF in this disease, we hypothesized that DF can be a treatment for our patients with PIMS-TS, which might also resemble a generalized endotheliitis.

The first patient, a 13-year old girl without any co-morbidities, was admitted for a diagnosis of appendicitis. After a laparoscopic appendectomy the patient was discharged in good clinical condition. Two weeks later, she presented with fever, headache, abdominal pain, nausea and altered sense of smell. An oropharyngeal swab was positive for SARS-Cov-2 by RT-PCR and she had IgG After informed consent by the legal guardians, DF was started as an off-label treatment at a dose of 4mg/kg every 6 hours for the first day followed by 6mg/kg every 6 hours for another 3 days together with low-dose heparin (5 units/kg/hr). After start of DF, D-dimers, troponin and bilirubin decreased rapidly while lymphocyte and platelet numbers increased ( Figure 1B ). No side effects of DF were seen, and the patient could be discharged after 9 days.

Since no other anti-inflammatory drug was given, the rapid response was attributed to the application of DF. Figure 1F ). The formed clot showed remarkable resistance toward TPA (lysis time [LT] in TPA-test: 520 sec, Figure 1F ). Given the laboratory tests and the clinical state, a diagnosis of PIMS-TS was made, and we started treatment with DF at a dose of 25 mg/kg/day divided into 4 doses together with low-dose heparin. After 3 doses of DF, the clot firmness was reduced (MCF: 50 mm, Figure 1G ) and TPAmediated lysis was significantly improved (LT: 360 sec, Figure 1G ). Although this is still speculative, our data indicate that the DF treatment might have supported the TPA-mediated clot lysis, probably via increasing plasmin concentration or downregulating the plasminogen activator inhibitor. After 8 days of DF treatment, the patient was afebrile and could be discharged 17 days after admission with normal laboratory results and without signs of ascites or pleural effusions.

A c c e p t e d M a n u s c r i p t 9 Both patients presented with fever and abdominal pain with an initial differential diagnosis of acute appendicitis and both had SARS-CoV-2 infection documented by positive pharyngeal swabs (PCR), by presence of anti-SARS-CoV-2 antibodies as well as detection of SARS-CoV-2-specific T cells ( Figures   1A, D) . The inflammatory status and laboratory tests were suggestive for the diagnosis of the recently described PIMS-TS. So far, no specific treatment for this syndrome has been reported. In a recent publication, 48 children with Covid-19 admitted to ICUs were described. Most children were treated with hydroxychloroquine. Other agents, mostly used in combinations were azithromycin, remdesivir and tocilizumab [8] . Feldstein et al describe pediatric patients with multisystem inflammatory syndrome who mainly received steroids, or IVIG in case of Kawasaki´s disease like features. None of these approaches are primarily directed towards the treatment of an assumed endothelial damage [9] . The reasons for the endotheliitis are currently not clear. It might be a direct toxic effect of the virus, since expression of ACE2 on endothelial cells can provide an entry mechanism for the virus. Another possible mechanism might be a complement-mediated injury either by direct complement activation or antibody-mediated [10] . Indeed, significant deposits of C5b-9 have been described in the lungs in autopsy cases [11] . Therefore, we measured the C5b-9 complex in patient 2 and found a two-fold elevated level A c c e p t e d M a n u s c r i p t 10 at time of admission which normalized during DF treatment ( Figure 1E ). Furthermore, one could speculate that higher titers of anti-SARS-CoV-2 IgM and/or IgG might induce enhanced complement-mediated endothelial damage since high specific IgG antibodies correlated with more severe illness and poorer outcome compared to patients with lower titers [12] .

Altogether, we favor the hypothesis of such a complement-mediated endothelial cell damage, which is further supported by increased numbers of endothelial cells and endothelial colony-forming cells in the peripheral blood of adults with severe illness (R. Handgretinger, unpublished observations). The endothelial damage in turn is associated with an increased risk of microthrombi [13] and hypofibrinolysis, which is also seen in Covid-19 patients (Bakchoul T. et al., manuscript submitted). Interestingly, we observed a normalization of the hypofibrinolytic state of patient 2 during DF infusions using the TPA test. Heparin possibly supplemented DF treatment, but is unlikely to exert the observed effects alone as a single agent.

Another observation was that patient 1 had most likely two waves of disease: the first wave was the Covid-19-associated appendicitis with capillaritis/endotheliitis while the second wave presented symptoms of PIMS-TS. One could speculate that this patient developed an antibody-mediated The membrane attack complex C5b-9 was measured at admission by ELISA. A two-fold elevated level was found compared to 4 healthy donors (grey bar depicts mean ±1 SD). During DF administration levels normalized.

A c c e p t e d M a n u s c r i p t 16 Blood samples from patient 2 showed increased clot firmness and remarkable resistance to clot lysis after subsequent induction of fibrinolysis by tissue plasmin activator (F). This finding was significantly improved after the initiation of DF treatment (G).

A c c e p t e d M a n u s c r i p t 17 Figure 1 

Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from COVID-19 Infection

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Endothelial cell infection and endotheliitis in COVID-19

Hyperinflammatory shock in children during COVID-19 pandemic

The role of the endothelium in the short-term complications of hematopoietic SCT

Drug safety evaluation of defibrotide

Defibrotide: properties and clinical use of an old/new drug

Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

The role of C5a in acute lung injury induced by highly pathogenic viral infections

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases

Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

This work was supported by grants from the excellence cluster iFIT (EXC 2180)[Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen der Exzellenzstrategie des Bundes und der Länder -WXC 2180 -390900677] to P.L. and A.R., from the Dieter Schwarz Stiftung Neckarsulm, from the Reinhold-

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 13